Personalis, Inc. (PSNL) - Long-Term Debt to Capital

Corporate emblem and logo of Personalis, Inc. (PSNL)

The Personalis, Inc. (PSNL) price chart on the GURU.Markets platform reflects a debt-to-equity ratio of 0.14. The business relies on high-precision NGS DNA sequencing to detect disease recurrence while expanding partnerships with pharmaceutical behemoths. The team brings together top bioinformaticians who develop personalized therapy regimens. Due to the precision of its genomic research, the brand is recognized as an authoritative innovator within the medical community.

Personalis Corp - PSNL Long-Term Debt to Capital (period 07/04/2022 - 10/30/2026)

Analytical breakdowns for Personalis, Inc.

- stock value and consensus price forecast:
Stock Quotes Personalis Inc|PSNL - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Personalis, Inc.|PSNL - Total Company Value
- company book value details:
Equity per Share Personalis|PSNL - Book Capitalization|Market Cap to Net Assets Ratio personalis.com|PSNL - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Personalis, Inc.|PSNL - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital personalis.com|PSNL - Company Total Debt|Debt to Net Assets Ratio Personalis, Inc.|PSNL - Company Long-Term Debts|Company Current Liabilities Personalis|Quick Ratio personalis.com
- financial results and valuation multiples details:
PSNL - Company Net Income
General company analysis:Personalis Inc - PSNL
Original product of personalis.com

This indicator determines the share of long-term liabilities within the equity structure, measuring financial leverage and the business's resilience to revenue declines. For Personalis, Inc. (PSNL), which invests in the development of MRD tests and partnerships with pharma behemoths, the long-term debt-to-equity ratio demonstrates the balance between debt-funded expansion and default risk, confirming the company's overall solvency.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|ERAS: Long-Term Debt to Capital|Long-Term Liabilities to Capital Delcath Corp (DCTH)|Long-Term Debt to Equity Y-mAbs Therapeutics|AURA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Long-Term Debt to Equity Ratio|CTOR: Long-Term Debt to Equity Ratio|HURA - Long-Term Debt to Capital|Protara Therapeutics, Inc. (TARA) - Long-Term Debt to Equity|Fate Therapeutics Inc - Long-Term Debt to Capital Coefficient|WHWK (Aadi Bioscience, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital TScan TCRX|Long-Term Debt to Equity Champions Oncology (CSBR)|XBIT: Long-Term Liabilities to Equity|Long-Term Debt to Capital CVM (CEL-SCI)|OS Therapies Inc. (OSTX) - Long-Term Liabilities to Capital|RADX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ARTV (Artiva Biotherapeutics, Inc.)|adlainortye.com (ANL) - Long-Term Debt to Equity|VERU - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Tempest Therapeutics, Inc.|Long-Term Liabilities to Capital Xilio XLO|Long-Term Debt to Equity Renovaro Inc. (RENB)|muraloncology.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KAPA (Kairos Pharma)|Long-Term Debt to Capital OnKure Therapeutics, Inc. OKUR|GDTC - Long-Term Debt to Equity|CRIS: Long-Term Debt to Equity|APLM: Long-Term Debt to Capital|THAR - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Advanced Biomed Inc.|genprex.com (GNPX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio CLDI (Calidi Biotherapeutics)|SBFM (Sunshine Biopharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XBIO (Xenetic Biosciences, Inc.)|Ratio of Long-Term Indebtedness to Capital Salarius Pharma (SLRX)|PPBT - Long-Term Debt to Equity|AONC (American Oncology Network) - Long-Term Debt to Capital Ratio|BGNE: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Checkpoint Therapeutics Inc.|Long-Term Debt to Equity Ratio ELEV|iCAD Corp (ICAD) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ikena Oncology, Inc. (IKNA)|NTBL: Long-Term Liabilities to Equity|Long-Term Debt to Equity Viracta Therapeutics, Inc. VIRX|Ratio of Long-Term Indebtedness to Capital MorphoSys Inc (MOR)|NAYA - Long-Term Debt to Equity|AAPGV (Ascentage) - Long-Term Debt to Capital Ratio